We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Macerich (MAC) Q1 FFO Beats Estimates, Revenues Fall Y/Y
Read MoreHide Full Article
Retail REIT The Macerich Company (MAC - Free Report) delivered first-quarter 2018 funds from operations (FFO) per share of 82 cents, beating the Zacks Consensus Estimate by a cent.
Results were backed by robust growth in re-leasing spreads and tenant sales growth. However, the company recorded lower portfolio occupancy.
The company posted revenues of $212 million for the first quarter, missing the Zacks Consensus Estimate of $215 million. Further, the figure came in 3.5% lower than the prior-year quarter figure.
Quarter in Detail
As of Mar 31, 2018, mall portfolio occupancy shrunk 30 basis points (bps) year over year to 94%. Mall tenant annual sales increased 7.4% year over year to $686 per square feet. Re-leasing spreads for the year ended Mar 31, 2018, increased 14.7%. Average rent per square foot ascended 3.8% to $58.44 from $56.31 as of Mar 31, 2017.
Also, same-center net operating income for the reported quarter inched up 0.07% from the prior-year period.
As of Mar 31, 2018, Macerich’s cash and cash equivalents summed $118.2 million, up from $91 million reported as of Dec 31, 2017.
Guidance
Macerich reaffirmed its guidance for 2018. The retail REIT expects FFO per share of $3.92-$4.02. This is backed by the same-center NOI growth rate projection of 2-2.5%, and no asset sales or acquisitions assumptions. Currently, the Zacks Consensus Estimate for full-year FFO per share is pegged at $3.95.
Our Viewpoint
The company has resorted to non-core asset dispositions and recycling the proceeds toward higher quality assets. It continued with this strategy in the Jan-Mar quarter as well. Such moves are expected to improve Macerich’s portfolio quality.
However, it is feared that dwindling footfall amid shift of consumers toward online channels, store closures and bankruptcy of retailers might affect the company’s near-term performance. While Macerich has been striving to counter the pressure through efforts to support omni-channel retailing and bringing online retailers to its stores, implementation of such measures requires a decent upfront cost. Therefore, this might consequently limit any robust growth in profit margins in the near future.
Macerich Company (The) Price, Consensus and EPS Surprise
Taubman Centersreported first-quarter 2018 adjusted FFO per share of $1.04, surpassing the Zacks Consensus Estimate of 92 cents. The figure also came in 13% higher than the year-ago tally of 92 cents.
Simon Property Group, Inc. (SPG - Free Report) delivered first-quarter 2018 FFO of $2.87 per share, which beat the Zacks Consensus Estimate of $2.83. The reported figure also came in 4.7% higher than the prior-year tally of $2.74.
Regency Centers Corporation’s (REG - Free Report) first-quarter 2018 FFO per share of 96 cents outpaced the Zacks Consensus Estimate of 94 cents. Further, results compared favorably with 27 cents reported in the year-earlier quarter. However, results in the year-ago period included one-time merger-related costs of 55 cents per share.
Note: Anything related to earnings presented in this write-up represent funds from operations (FFO) — a widely used metric to gauge the performance of REITs.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Image: Bigstock
Macerich (MAC) Q1 FFO Beats Estimates, Revenues Fall Y/Y
Retail REIT The Macerich Company (MAC - Free Report) delivered first-quarter 2018 funds from operations (FFO) per share of 82 cents, beating the Zacks Consensus Estimate by a cent.
Results were backed by robust growth in re-leasing spreads and tenant sales growth. However, the company recorded lower portfolio occupancy.
The company posted revenues of $212 million for the first quarter, missing the Zacks Consensus Estimate of $215 million. Further, the figure came in 3.5% lower than the prior-year quarter figure.
Quarter in Detail
As of Mar 31, 2018, mall portfolio occupancy shrunk 30 basis points (bps) year over year to 94%. Mall tenant annual sales increased 7.4% year over year to $686 per square feet. Re-leasing spreads for the year ended Mar 31, 2018, increased 14.7%. Average rent per square foot ascended 3.8% to $58.44 from $56.31 as of Mar 31, 2017.
Also, same-center net operating income for the reported quarter inched up 0.07% from the prior-year period.
As of Mar 31, 2018, Macerich’s cash and cash equivalents summed $118.2 million, up from $91 million reported as of Dec 31, 2017.
Guidance
Macerich reaffirmed its guidance for 2018. The retail REIT expects FFO per share of $3.92-$4.02. This is backed by the same-center NOI growth rate projection of 2-2.5%, and no asset sales or acquisitions assumptions. Currently, the Zacks Consensus Estimate for full-year FFO per share is pegged at $3.95.
Our Viewpoint
The company has resorted to non-core asset dispositions and recycling the proceeds toward higher quality assets. It continued with this strategy in the Jan-Mar quarter as well. Such moves are expected to improve Macerich’s portfolio quality.
However, it is feared that dwindling footfall amid shift of consumers toward online channels, store closures and bankruptcy of retailers might affect the company’s near-term performance. While Macerich has been striving to counter the pressure through efforts to support omni-channel retailing and bringing online retailers to its stores, implementation of such measures requires a decent upfront cost. Therefore, this might consequently limit any robust growth in profit margins in the near future.
Macerich Company (The) Price, Consensus and EPS Surprise
Macerich Company (The) Price, Consensus and EPS Surprise | Macerich Company (The) Quote
Currently, Macerich has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Performance of Other Stocks
Taubman Centersreported first-quarter 2018 adjusted FFO per share of $1.04, surpassing the Zacks Consensus Estimate of 92 cents. The figure also came in 13% higher than the year-ago tally of 92 cents.
Simon Property Group, Inc. (SPG - Free Report) delivered first-quarter 2018 FFO of $2.87 per share, which beat the Zacks Consensus Estimate of $2.83. The reported figure also came in 4.7% higher than the prior-year tally of $2.74.
Regency Centers Corporation’s (REG - Free Report) first-quarter 2018 FFO per share of 96 cents outpaced the Zacks Consensus Estimate of 94 cents. Further, results compared favorably with 27 cents reported in the year-earlier quarter. However, results in the year-ago period included one-time merger-related costs of 55 cents per share.
Note: Anything related to earnings presented in this write-up represent funds from operations (FFO) — a widely used metric to gauge the performance of REITs.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>